insights_auto
Why is MVIR up 5.77%?
Dive Deeperchevron_right
MVIR:STO
Medivir AB
SEKÂ 1.69
arrow_upward
+5.77%(+0.092) 1D
Oct 2, 5:29:51 PM GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
SEKÂ 1.71
High
SEKÂ 1.78
Low
SEKÂ 1.67
Mkt. cap
1.05B
Avg. vol.
1.88M
Volume
0.00
52-wk high
SEKÂ 2.88
52-wk low
SEKÂ 0.34
EPS
-SEKÂ 0.37
Shares outstanding
624.18M
No. of employees
6
Open
SEKÂ 1.71
High
SEKÂ 1.78
Low
SEKÂ 1.67
Mkt. cap
1.05B
Avg. vol.
1.88M
Volume
0.00
52-wk high
SEKÂ 2.88
52-wk low
SEKÂ 0.34
EPS
-SEKÂ 0.37
Shares outstanding
624.18M
No. of employees
6
News stories
From web sources and news partners
FXLeaders
·
1 hour ago
Dow Jones and Nasdaq Futures Open Higher as Buyers Target New Records
Moomoo
·
1 day ago
Dow Jones Top Performers of 2026 So Far:
InteractiveCrypto
·
11 hours ago
The S&P 500 Looks Strong. Underneath, October Looks Thin.
Traders Union
·
5 hours ago
S&P500 has posted gains in nearly every November-through-June period since 1942, Lia Holmgren notes
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB